The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis

被引:9
|
作者
Raballo, Andrea [1 ,2 ]
Poletti, Michele [3 ]
Preti, Antonio [4 ]
机构
[1] Univ Svizzera Italiana USI, Fac Biomed Sci, Chair Psychiat, Lugano, Switzerland
[2] Cantonal Socio Psychiat Org OSC, Publ Hlth Div, Dept Hlth & Social Care, Mendrisio, Switzerland
[3] Azienda USL IRCCS Reggio Emilia, Dept Mental Hlth & Pathol Addict, Child & Adolescent Neuropsychiat Serv, Reggio Emilia, Italy
[4] Univ Turin, Dept Neurosci, Turin, Italy
关键词
RANDOMIZED CONTROLLED-TRIAL; ULTRA-HIGH RISK; MENTAL STATE; SCHIZOPHRENIA; PREDICTORS; INTERVENTIONS; CONVERSION; SYMPTOMS; DISORDER; CORTISOL;
D O I
10.1038/s41398-023-02405-6
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Meta-analytic evidence indicates that baseline exposure to antipsychotics (AP) in individuals at clinical high-risk for psychosis (CHR-P) is associated with an even higher risk of transition to psychosis. However, the temporal dynamics of such prognostic effect have not been clarified yet. This study was therefore designed to address this knowledge gap. We performed a systematic review and meta-analysis of all longitudinal studies published up to 31 December 2021 on CHR-P individuals identified according to a validated diagnostic procedure and reporting numeric data of transition to psychosis according to baseline antipsychotic exposure. 28 studies covering a total of 2405 CHR-P were included. 554 (23.0%) were exposed to AP at baseline, whereas 1851 (77.0%) were not. At follow-up (12 to 72 months), 182 individuals among AP-exposed (32.9%; 95% CI: 29.4% to 37.8%) and 382 among AP-naive CHR-P (20.6%; 18.8% to 22.8%) developed psychosis. Transition rates increased over time, with the best-fit for an ascending curve peaking at 24 months and reaching then a plateau, with a further increase at 48 months. Baseline AP-exposed CHR-P had higher transition risk at 12 months and then again at 36 and 48 months, with an overall higher risk of transition (fixed-effect model: risk ratio = 1.56 [95% CI: 1.32-1.85]; z = 5.32; p < 0.0001; Random-effect model: risk ratio = 1.56 [95% CI: 1.07-2.26]; z = 2.54; p = 0.0196). In conclusion, the temporal dynamics of transition to psychosis differ in AP-exposed vs. AP-naive CHR-P. Baseline AP exposure in CHR-P is associated with a persistently higher risk of transition at follow up, supporting the rationale for more stringent clinical monitoring in AP-exposed CHR-P. The insufficiency of more granular information in available primary literature (e.g., temporal and quantitative details of AP exposure as well as psychopathological dimensions in CHR-P) did not allow the testing of causal hypotheses on this negative prognostic association.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis
    Andrea Raballo
    Michele Poletti
    Antonio Preti
    [J]. Translational Psychiatry, 13
  • [2] Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis
    Raballo, Andrea
    Poletti, Michele
    Preti, Antonio
    [J]. PSYCHOLOGICAL MEDICINE, 2023, 53 (14) : 6417 - 6423
  • [3] Letter to the Editor on 'Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis'
    Livingston, Nicholas R.
    Fusar-Poli, Paolo
    Modinos, Gemma
    [J]. PSYCHOLOGICAL MEDICINE, 2024, 54 (01) : 215 - 216
  • [4] Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis
    Raballo, Andrea
    Poletti, Michele
    Preti, Antonio
    [J]. PSYCHOLOGICAL MEDICINE, 2023, 53 (10) : 4550 - 4560
  • [5] Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?
    Raballo, Andrea
    Poletti, Michele
    Preti, Antonio
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2021, 24 (09): : 710 - 720
  • [6] The Clinical High-Risk State for Psychosis (CHR-P), Version II
    Fusar-Poli, Paolo
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 (01) : 44 - 47
  • [7] EPIDEMIOLOGY AND DIAGNOSIS OF CLINICAL HIGH-RISK STATE FOR PSYCHOSIS (CHR-P) SYNDROMES
    Menefee, Elizabeth
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2022, 61 (10): : S84 - S84
  • [8] Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?
    Khoury, Rita
    Nasrallah, Henry A.
    [J]. SCHIZOPHRENIA RESEARCH, 2018, 199 : 31 - 38
  • [9] Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk
    Raballo, Andrea
    Poletti, Michele
    Preti, Antonio
    [J]. JAMA PSYCHIATRY, 2024, 81 (07) : 727 - 730
  • [10] Clinical High-Risk for Psychosis (CHR-P) circa 2024: Synoptic analysis and synthesis of contemporary treatment guidelines
    Poletti, Michele
    Pelizza, Lorenzo
    Preti, Antonio
    Raballo, Andrea
    [J]. ASIAN JOURNAL OF PSYCHIATRY, 2024, 100